# US 2020/0400651 A1 · Method of using human spheroids for drug discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400651 A1
- Document ID: US20200400651A1
- Status: Published application
- Kind: A1
- Application number: 16/778,283
- Filed: 2020-01-31
- Published: 2020-12-24
- Earliest claimed: 2019-02-02
- Assignees: StemoniX Inc.
- Applicants: StemoniX Inc
- Inventors: Cassiano Carromeu
- Web page: https://patentgrep.com/patent/US20200400651A1

## CPC

- G01N 33/5058: {Neurological cells}
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/433: Thidiazoles
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- C12N 5/0619: {Neurons}
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C12N 2502/081: neurons
- C12N 2502/086: glial cells
- C12N 2503/02: Drug screening
- C12N 2503/04: Screening or testing on artificial tissues
- C12N 2513/00: 3D culture
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

## Claims

### Claim 1

A method to detect the effect of one or more compounds on spheroids, comprising:
contacting one or more spheroids of human cells of uniform diameter and one or more test compounds, wherein the spheroids are obtained from cells of an autism patient, cells of a Rett syndrome patient, or cells that are from a model of Rett syndrome; and
detecting the effect of the one or more compounds on one or more of the spheroids.

### Claim 2 (depends on 1)

The method of claim 1 wherein the one or more spheroids are in wells of a multi-well plate.

### Claim 3 (depends on 2)

The method of claim 2 wherein each well has one spheroid.

### Claim 4 (depends on 2)

The method of claim 2 wherein the wells are further contacted with a fluorescent molecule useful to detect calcium, and the amount or change in fluorescence over time is detected in one or more wells.

### Claim 5 (depends on 4)

The method of claim 4 wherein the amount or change in fluorescence is detecting a quantity of peaks of fluorescence, an amplitude of one or more of the peaks, peak spacing between one or more of the peaks, a width of one or more peaks, or any combination thereof.

### Claim 6 (depends on 1)

The method of claim 1 wherein the one or more spheroids comprise neurons.

### Claim 7 (depends on 1)

The method of claim 1 wherein the one or more spheroids comprise neurons and astrocytes.

### Claim 8 (depends on 1)

The method of claim 1 wherein the one or more spheroids comprise cells from a Rett disease patient

### Claim 9 (depends on 1)

The method of claim 1 wherein the one or more spheroids comprise microglial cells or oligodendrocytes.

### Claim 10 (depends on 1)

The method of claim 1 wherein the one or more spheroids have a diameter of about 450 to about 600 microns.

### Claim 11 (depends on 1)

The method of claim 1 wherein the one or more spheroids are cultured for at least 4 to 6 weeks before contacting with the one or more test compounds.

### Claim 12 (depends on 3)

The method of claim 3 wherein the fluorescent molecule comprises Calcium 3, Calcium 4, Calcium 5, Calcium 6, Fluo 3, or Fluo4.

### Claim 13 (depends on 3)

The method of claim 3 wherein the amount of change in fluorescence is compared to the fluorescence in a well with spheroids and the fluorescent molecule but no test compound.

### Claim 14

A method or prevent, inhibit or treat one or more symptoms of Rett syndrome in a human, comprising: administering to the patient a composition comprising an effective amount of one or more of a 5-HT4 receptor selective agonist, a zabicycloalkyl benzimidazolone, a GABA receptor antagonist, a benzodiazepine, a competitive antagonist at the benzodiazepine receptor, an acetazolamide, a selective noradrenaline reuptake inhibitor, an antimuscarinic, a selective serotonin receptor agonist, a compound that enhances release of gonadotropin releasing hormone, a selective serotonin reuptake inhibitor, a branched-chain saturated fatty acid anion, an inhibitor of CYP2C9, an inhibitor of glucuronyl transferase, an inhibitor of histone deacetylase, an inhibitor of epoxide hydrolase, a gamma-aminobutyric acid (GABA) agonist, a nonsteroidal anti-inflammatory drug (NSAID), a biindole, an anticholinergic, a dopamine antagonist, an acetylcholinesterase inhibitor, an antihistamine, a benzothiadiazine, a modulator of glutamate AMPA receptors, an anti-emetic, a serotonin inverse agonist, an inhibitor of monoamine oxidase, or an alkaloid, or any combination thereof.

### Claim 15 (depends on 14)

The method of claim 14 wherein the composition comprises acetazolamide, atomoxetine (tomoxetine), benzhexol hydrochloride, BIMU-8, eletriptan HBr Salt, iloperidone, trazodone (Beneficat), valproate DPA, baclofen, benzydiamine hydrochloride, bromoindirubin-3-oxime, biperiden, citalopram, clebopride malate, bonepezil, flumazenil, hydroxyzine dichloride, IDRA-21, ondansetron, paroxetine, pinmavanserin, pirlindole mesylate, selegiline hydrochloride, or vinpocetine, or any combination thereof.

### Claim 16 (depends on 14)

The method of claim 14 wherein the composition is orally administered.

### Claim 17 (depends on 14)

The method of claim 14 wherein the composition is a sustained release formulation.

### Claim 18 (depends on 14)

The method of claim 14 wherein administration is intravenous, intra-arterial, subcutaneous, intranasal, intrathecal, intracerebroventricular, intraparenchymal, trans-retinal, intramuscular, transdermal, or rectal.

### Claim 19 (depends on 14)

The method of claim 14 wherein the composition is a sustained release formulation.

### Claim 20 (depends on 14)

The method of claim 14 wherein the amount inhibits or treats delayed growth, loss of normal movement, loss of coordination, loss of communication abilities, abnormal hand movements, abnormal eye movements, breathing problems, cognitive disabilities, seizures, scoliosis, irregular heartbeat, or sleep disturbances
